Drug Name: Pluvicto
Active Ingredient: lutetium (177Lu) vipivotide tetraxetan
Indications: To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies
Approval Date: 3/23/2022
Company: Advanced Accelerator Applications USA, Inc, Novartis AG
More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf